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INTRODUCTION: Theburden of hepatocellular carcinoma (HCC) occurring in patientswith alcoholic liver disease (ALD) is
increasing at an alarming rate. The aims of this study were to compare the patient and tumor
characteristics of HCC occurring in ALD-alone relative to and in addition to other chronic liver diseases.
METHODS: Patients diagnosed with HCC between 2000 and 2014 were identified at 5 US clinical centers. The
patients were categorized as ALD-alone, ALD plus viral hepatitis, or a non-ALD etiology. Clinical and
tumor characteristics among the 3 groupswere compared, and survival probability was estimated by the
Kaplan-Meier method. The frequency of noncirrhotic HCC was compared across the 3 groups.
RESULTS: A total of 5,327 patients with HCC were analyzed. Six hundred seventy (12.6%) developed HCC due to
underlying ALD.Ninety-one percent of ALD-relatedHCC arose inmen, in contrast to non-ALD etiologies
where men accounted for 70% of HCCs cases (P < 0.001). Patients with ALD-alone-related HCC were
older at diagnosis and had tumors less likely to be detected as part of routine surveillance. The ALD-
alone cohort was least likely to be within the Milan criteria and to undergo liver transplantation. Overall
survival in the ALD-aloneHCC cohort was lower than the other 2 groups (1.07 vs 1.31 vs 1.41 years,P<
0.001). HCC in the noncirrhotic ALD cohorts occurred in only 3.5% of the patients compared with
15.7% in patients with non-ALD etiologies (P < 0.001).
DISCUSSION: HCC occurring in patients with ALD occurred mostly in older men and almost exclusively in a cirrhotic
background.Theypresentwithadvanced tumors, and their survival is lower thanHCCsoccurring innon-ALD.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A223
Clinical and Translational Gastroenterology 2020;11:e00139. https://doi.org/10.14309/ctg.0000000000000139
INTRODUCTION
Alcohol use has a universal impact on public health and pro-
ductivity. The Global Status Report on Alcohol and Health from
2016 reported a prevalence of alcohol consumption in high socio-
demographic index areas of 72% in women and 83% in men with
average daily consumption of 1.9 and 2.9 standard drinks, re-
spectively (1). This alarming degree of alcohol consumption
worldwide translates to an increasing burden of alcoholic liver
disease (ALD) and its related complications. In 2016, there were an
estimated 1.25 million deaths due to cirrhosis and chronic liver
disease (CLD), of which 334,900 (27%)were due to alcohol (2). The
age-standardized adult liver transplant waitlist rate for ALD nearly
doubled between 2007 and2016 (3), andALDhas replacedhepatitis
C as the leading indication for liver transplantation in the United
States (4). A recent population-based study using the US Census
and national mortality data from 2007 to 2016 found a 4.5 annual
percentage increase in cirrhosis-related mortality from ALD (5).
Mortality in ALD often results from the development of he-
patocellular carcinoma (HCC). HCC is now the fourth most
common cause of cancer-related death worldwide (6). In 2015,
alcohol was responsible for 245,000 or 30% of all HCC deaths (7).
The World Health Organization estimates that more than 1
million people will die of HCC in 2030 (8). The confluence of
increased alcohol exposure together with the increase in incident
HCCs creates an urgent need to better understand the relation-
ship between alcohol use, ALD, and HCC.
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Patients with ALD-related HCCs present with advanced
tumors often due to a delay in diagnosis from a lack of surveillance
(9–11). European cohort studies have shown a reduction in the
median overall survival of ALD-related HCCs compared with
Hepatitis C (HCV)-relatedHCCs after adjusting for lead time bias,
but the prognostic significance of alcohol did not persist after
stratifying by Barcelona-Clinic Liver Cancer stage (10,12). Thus,
liver function and tumor characteristics at diagnosis seem to affect
survival more than the underlying etiology of liver disease (13).
Old age and male gender are established risk factors for HCC
in ALD and were recently shown to be independently associated
with the development of HCC in a prospective trial of patients
with alcohol-related cirrhosis undergoing surveillance in France
(13,14). Environmental factors such as diabetes and body mass
index (BMI) may also influence the occurrence of HCC and to-
gether with age and gender were recently included in an HCC
prognostic model that successfully risk stratified patients with
alcohol and nonalcoholic fatty liver disease (NAFLD)-related
cirrhosis (15). Finally, genetic variants in PNPLA3 and TM6SF2
confer increased susceptibility to HCC in patients with ALD.
Interestingly, the presence of both risk alleles accounted for half of
the attributable risk of HCC in a study of approximately 2,000
patients across Europe (16). Although similar patient, environ-
mental, and genetic factors affect HCC risk, particularly for al-
cohol andNAFLD-relatedHCC, the contribution of each variable
undoubtedly differs based on liver disease etiology.
Our study aims to characterize distinctive features and out-
comes of HCC in patients with ALD. We studied 5,327 patients
with HCC seen at 5 major liver centers across the United States
over a 14.5-year period between 2000 and 2014. We contrasted
HCCs in patients with ALD exclusively and in combination with
viral hepatitis to HCC cases that occurred in the absence of
documented ALD. In view of the recent trend of younger patients
presenting with ALD and the effect of alcohol metabolites in
directly promoting hepatic carcinogenesis (17,18), we included in
our analysis a substantial subset of HCCs from noncirrhotic
patients to determine the frequency of noncirrhotic ALD-related
HCC from our cohort as well.
METHODS
Cohort compilation
A detailed description of the ascertainment and characterization
of the cohort is available for review in the study by Gawrieh et al.
(19). Each participating site had local institutional review board
approval to conduct the study. Briefly, we retrospectively iden-
tified HCC cases between January 2000 and June 2014 using
center-specific cancer registries, manually reviewed the health
record to verify the diagnosis, and extracted relevant data into
a shared database coordinated at Indiana University. A diagnosis
of HCC required histological and/or radiographic evidence
consistent with the American Association for Study of Liver
Disease guidelines (20). Tumor characteristics including alpha
fetoprotein, largest tumor diameter, Tumor, Node, Metastasis
stage, and whether the HCC was within the Milan criteria were
captured at the time of diagnosis (21,22). All HCC treatment
modalities were recorded from the medical record for analysis as
well.
Figure 1. HCC cohort stratified by CLD etiology. CLD, chronic liver disease; HCC, hepatocellular carcinoma; NAFLD, nonalcoholic fatty liver disease.
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Table 1. Patient and disease characteristics for alcohol alone vs nonalcohol etiology
Variable Overall, N5 4,101 Alcohol alone, N 5 670 Nonalcohol etiology, N 5 3,431 P value
Age (yr) 63.0 (56.0, 70.0) 65.0 (59.0, 71.0) 62.0 (56.0, 70.0) ,0.001
Male sex 3,009 (73.4%) 610 (91.0%) 2,399 (69.9%) ,0.001
Race
White 2,832 (70.1%) 492 (74.1%) 2,340 (69.4%)
Black 406 (10.1%) 49 (7.4%) 357 (10.6%)
Hispanic 436 (10.8%) 108 (16.3%) 328 (9.7%) ,0.001
Asian 176 (4.4%) 5 (0.8%) 171 (5.1%)
Other 188 (4.7%) 10 (1.5%) 178 (5.3%)
BMI (kg/m2) 27.8 (24.4, 31.9) 28.6 (24.9, 32.6) 27.6 (24.3, 31.7) 0.009
Obesity 1,232 (35.2%) 238 (40.5%) 994 (34.2%) 0.004
Diabetes 1,681 (41.3%) 295 (44.6%) 1,386 (40.7%) 0.06
Hypertension 2,608 (64.1%) 444 (67.1%) 2,164 (63.5%) 0.08
Dyslipidemia 1,110 (27.3%) 180 (27.4%) 930 (27.3%) 0.98
Coronary artery disease 785 (19.3%) 134 (20.3%) 651 (19.1%) 0.50
Peripheral vascular disease 343 (8.5%) 77 (11.7%) 266 (7.8%) 0.001
ALT (units/L) 47.0 (30.0, 80.0) 39.0 (26.0, 63.0) 49.0 (31.0, 84.0) ,0.001
AST (units/L) 73.0 (45.0, 125.0) 61.0 (41.0, 111.0) 75.0 (46.0, 128.0) ,0.001
Total bilirubin (mg/dL) 1.1 (0.7, 2.0) 1.2 (0.7, 2.1) 1.1 (0.7, 1.9) 0.001
Alkaline phosphatase (units/L) 138.0 (96.0, 211.0) 153.5 (105.0, 230.0) 135.0 (94.0, 207.0) ,0.001
Albumin (g/dL) 3.5 (3.0, 4.0) 3.4 (2.9, 3.9) 3.5 (3.0, 4.0) 0.002
Platelets (K/mm3) 149.0 (90.0, 236.0) 146.0 (91.0, 221.0) 150.0 (90.0, 238.0) 0.33
Creatinine (mg/dL) 0.9 (0.8, 1.1) 0.9 (0.8, 1.2) 0.9 (0.7, 1.1) 0.009
INR 1.2 (1.1, 1.3) 1.2 (1.1, 1.4) 1.2 (1.1, 1.3) 0.001
MELD score 10.0 (8.0, 14.0) 11.0 (8.0, 14.0) 10.0 (8.0, 14.0) ,0.001
APRI score 1.4 (0.7, 2.7) 1.2 (0.7, 2.2) 1.5 (0.7, 2.8) 0.001
APRI category
,1.0 1,402 (37.6%) 251 (40.7%) 1,151 (37.0%)
1.0–2.0 975 (26.1%) 188 (30.5%) 787 (25.3%) ,0.001
.2.0 1,354 (36.3%) 177 (28.7%) 1,177 (37.8%)
Is cirrhosis present? (Y/N/unclassified)
No 583 (14.2%) 44 (6.6%) 539 (15.7%)
Yes 3,349 (81.7%) 611 (91.2%) 2,738 (79.8%) ,0.001
Unclassified 169 (4.1%) 15 (2.2%) 154 (4.5%)
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Adiagnosis of alcohol-relatedHCC required evidence by chart
review of a physicians’ documentation of alcohol use disorder,
defined as a history of more than 3 drinks a day, clinical docu-
mentation of alcoholism/alcohol use disorder, enrollment in
a substance abuse treatment program, or a history of alcoholic
hepatitis. Other etiologies of CLD were similarly determined by
a chart review of hepatologist’s notes and/or confirmatory labo-
ratory testing.Wemanually extracted liver-related complications,
the presence of comorbid metabolic risk factors, and laboratory
tests of hepatic function to calculate the model for end-stage liver
disease (MELD) and Pugh-Child scores. The patients were clas-
sified as either cirrhotic, noncirrhotic, or unclassified according to
the criteria published previously by Mittal et al. and externally
validated by our consortium (19,23). Patient survival was estab-
lished from cancer registries and medical records. For patients
who are still alive or died with an unknown date of death, the date
of the last contact available in the medical record was used to
define the time of censoring for the survival analysis.
Statistical analyses
HCCcases were categorized into 3 groups for analysis: (i) alcohol
alone, (ii) alcohol plus viral etiology forCLD, or (iii) a nonalcohol
etiology. The last cohort was further divided for a subgroup
analysis ofNAFLDalone vs alcohol alone.We also contrasted the
3 groups by 3 different eras of diagnosis: 2000–2004, 2005–2009,
and 2010–2014. Categorical variables were summarized and
compared using the x2 test. Continuous variables were expressed
as median with interquartile range, and the Kruskal-Wallis test
was used to assess for significance. The overall survival proba-
bility was estimated by the Kaplan-Meier method and compared
between the 3 groups using the log-rank test. All analyses were
performed using SAS version 9.4 (SAS Institute, Cary, NC).
RESULTS
Prevalence of alcohol-related HCC in the study cohort
A study flow diagram is depicted in Figure 1. Five thousand three
hundred twenty-seven patients with HCC were included in the
analysis. 11.4%were classified as noncirrhotic, whereas 85.2% had
confirmed cirrhosis. ALD-alone was identified as the CLD in
12.6% (n 5 670) of patients, whereas ALD plus viral hepatitis
(94.4%—chronic hepatitis C) was the combined liver disease in
23% (n 5 1,226). The third cohort (n 5 3,431) included the
remaining 64.4% of patients with HCC but without an ALD di-
agnosis, the majority of whom had CLD because of either chronic
hepatitis C (42.9%), hepatitis B (10.1%), or NAFLD (24.3%).
Characteristics of patients with HCC from ALD
In comparison to the cohort of patients without ALD, patients
with alcohol-alone-related HCC were overwhelmingly men
(91% vs 70%, P, 0.001) (Table 1). Theywere also older (65 vs 62
years, P, 0.001), had higher BMIs (28.6 vs 27.6, P5 0.009), and
were more likely to be of white and/or Hispanic ethnicity (90.4%
vs 78.5%, P , 0.001). The alcohol-alone group had more ad-
vanced liver disease, as denoted by a higher medianMELD score
(11 vs 10, P, 0.001), and Child-Pugh class B/C status (51.6% vs
41.2%, P , 0.001). Other selected clinical and biochemical fea-
tures between the 2 groups are summarized in Table 1.
The cohort of patients with ALD plus viral hepatitis in contrast
to the group without ALD was diagnosed with HCC at a signifi-
cantly younger age (57 vs 62 years, P, 0.001) and had lower BMI
(26.9 vs 27.6, P5 0.0005) and lower frequency of obesity (29.1% vsT
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Table 2. Patient and disease characteristics comparing alcohol plus viral etiology and nonalcohol etiologies
Variable Overall, N 5 4,657 Alcohol plus viral etiology, N 5 1,226 Nonalcohol etiology, N 5 3,431 P value
Age (yr) 60.0 (55.0, 68.0) 57.0 (53.0, 61.0) 62.0 (56.0, 70.0) ,0.001
Male sex 3,514 (75.5%) 1,115 (90.9%) 2,399 (69.9%) ,0.001
Race
White 3,204 (69.9%) 864 (71.3%) 2,340 (69.4%)
Black 586 (12.8%) 229 (18.9%) 357 (10.6%)
Hispanic 413 (9.0%) 85 (7.0%) 328 (9.7%) ,0.001
Asian 189 (4.1%) 18 (1.5%) 171 (5.1%)
Other 194 (4.2%) 16 (1.3%) 178 (5.3%)
BMI (kg/m2) 27.4 (24.2, 31.5) 26.9 (24.0, 30.7) 27.6 (24.3, 31.7) 0.0005
Obesity 1,321 (32.7%) 327 (29.1%) 994 (34.2%) ,0.001
Diabetes 1,714 (37.0%) 328 (26.8%) 1,386 (40.7%) ,0.001
Hypertension 2,849 (61.5%) 685 (56.0%) 2,164 (63.5%) ,0.001
Dyslipidemia 1,098 (23.7%) 168 (13.8%) 930 (27.3%) ,0.001
Coronary artery disease 788 (17.0%) 137 (11.2%) 651 (19.1%) ,0.001
Peripheral vascular disease 343 (8.5%) 77 (11.7%) 266 (7.8%) 0.001
ALT (units/L) 53.0 (33.0, 87.0) 61.0 (39.0, 93.0) 49.0 (31.0, 84.0) ,0.001
AST (units/L) 79.0 (50.0, 131.0) 92.0 (62.0, 138.0) 75.0 (46.0, 128.0) ,0.001
Total bilirubin (mg/dL) 1.1 (0.7, 2.0) 1.4 (0.9, 2.2) 1.1 (0.7, 1.9) ,0.001
Alkaline phosphatase (units/L) 135.0 (96.0, 202.0) 134.0 (100.0, 189.0) 135.0 (94.0, 207.0) 0.71
Albumin (g/dL) 3.4 (2.9, 4.0) 3.2 (2.7, 3.7) 3.5 (3.0, 4.0) ,0.001
Platelets (K/mm3) 135.0 (84.0, 218.0) 106.0 (72.0, 159.0) 150.0 (90.0, 238.0) ,0.001
Creatinine (mg/dL) 0.9 (0.7, 1.1) 0.9 (0.7, 1.1) 0.9 (0.7, 1.1) 0.02
INR 1.2 (1.1, 1.4) 1.2 (1.1, 1.4) 1.2 (1.1, 1.3) ,0.001
MELD score 10.0 (8.0, 14.0) 11.0 (8.0, 14.0) 10.0 (8.0, 14.0) ,0.001
APRI score 1.7 (0.8, 3.2) 2.3 (1.3, 4.0) 1.5 (0.7, 2.8) ,0.001
APRI category
,1.0 1,347 (31.6%) 196 (17.0%) 1,151 (37.0%)
1.0–2.0 1,066 (25.0%) 279 (24.3%) 787 (25.3%) ,0.001
.2.0 1,852 (43.4%) 675 (58.7%) 1,177 (37.8%)
Is cirrhosis present? (Y/N/unclassified)
No 561 (12.0%) 22 (1.8%) 539 (15.7%)
Yes 3,928 (84.3%) 1,190 (97.1%) 2,738 (79.8%) ,0.001
Unclassified 168 (3.6%) 14 (1.1%) 154 (4.5%)
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34.2%, P , 0.001) and diabetes (26.6% vs 40.7%, P , 0.001)
(Table 2). Similar to the alcohol-alone group, the ALD and viral
cohortwerepredominantlymen (91%vs 70%,P,0.001) andwere
more decompensated at the time of HCC diagnosis with a higher
median MELD score and significantly more portal hypertensive-
related complications (Table 2). The combined ALD plus viral
cohort of patients also had comparatively more clinical features of
decompensated cirrhosis than the ALD-alone cohort (see Table 1,
Supplementary Digital Content 1, http://links.lww.com/CTG/
A223). Although these 2 groups did not differ in median MELD
score at time of HCC diagnosis, the combined ALD and viral
cohort had more hepatic synthetic dysfunction, as illustrated by
significantly lower albumin (3.2 vs 3.5 g/dL, P, 0.001) and higher
total bilirubin (1.4 vs 1.1 mg/dL, P , 0.001). The features of
metabolic syndrome including obesity, diabetes mellitus, hyper-
tension, and dyslipidemia were less frequently encountered in the
combined ALD and viral cohort compared with both the alcohol-
alone cohort and the nonalcohol cohort (P , 0.001 for each risk
factor, Table 2 and see Table 1, Supplementary Digital Content 1,
http://links.lww.com/CTG/A223).
Tumor characteristics in patients with ALD-related HCC
The ALD-alone and non-ALD cohorts did not differ in largest
tumor size (4.7 cm) (Table 3). However, the ALD-alone group was
significantly less likely to be diagnosed with HCC as part of
screening (21.6% vs 28.4%, P 5 0.001) and more likely to present
incidentally (15.8% vs 12.5%, P 5 0.04) or as part of symptoms
workup (59.9% vs 54.5%, P 5 0.02) (Table 3). Comparatively, the
ALD plus viral cohort presented with smaller tumors than the non-
ALDandALD-alone cohorts (3.7 vs 4.7 cm,P,0.001) (Table 4 and
seeTable 2, SupplementaryDigitalContent 1, http://links.lww.com/
CTG/A223). A small but significant difference in the rate of routine
screening as thediagnosticHCCmethodologywas seenbetween the
ALD and viral vs alcohol-alone cohort (26.3% vs 21.6%, P5 0.04),
although the alcohol-alone cohort had a noticeably higher rate for
the diagnosis of HCC to occur incidentally (15.8% vs 9%, P ,
0.001). A histologic HCC diagnosis was statistically less likely to
occur in the alcohol plus viral cohort (55%) in comparison to both
the nonalcohol group (69.8%, P, 0.001, Table 4) and the alcohol-
alone group (67.3%, P, 0.001, see Table 2, Supplementary Digital
Content 1, http://links.lww.com/CTG/A223).
The HCCs diagnosed in the ALD-alone and nonalcohol groups
didnotdifferby anatomic stageor frequencywithin theMilan criteria
at the time of diagnosis. However, both ALD-alone and nonalcohol
groupspresentedwith significantlyhigher stageHCC(stage III or IV)
than the ALD and viral group (51.5% and 48.3% vs 41.5%, re-
spectively, P for both #0.001). Not surprisingly, therefore, the
patients in the ALD and viral cohort weremore likely to present with
HCCwithin theMilan Criteria (30% and 34.4% vs 42%, respectively,
P for both,0.001). Selected differences in tumor characteristics be-
tween groups are summarized in Tables 3 and 4, and see Table 2,
Supplementary Digital Content 1, http://links.lww.com/CTG/A223).
Alcohol-alone vs NAFLD subgroup analysis
We compared the ALD-alone-related HCC cohort to the sub-
group of 790 NAFLD-related HCCs from the overall 3,341 non-
alcohol cohort. TheNAFLDHCCcaseswere diagnosed at anolder
age than the ALD-alone cohort (65 vs 68 years, P , 0.001). The
male gender disparity inHCC caseswas evenmore pronounced in
the subgroup analysis (91% vs 64.6%, P, 0.001). The ALD-alone
group had a higher total bilirubin (1.2 vs 0.9 mg/dL, P , 0.001),T
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Table 3. Tumor characteristics comparing alcohol-alone with nonalcohol etiology
Variable Overall, N 5 4,101 Alcohol alone, N 5 670 Nonalcohol etiology, N 5 3,431 P value
Tumor size (cm) 4.7 (2.7, 8.7) 4.7 (3.0, 8.1) 4.7 (2.7, 8.9) 0.93
AFP (ng/mL) 37.2 (6.4, 876.1) 25.8 (5.5, 876.1) 41.2 (6.7, 872.3) 0.03
AFP category
,20 1,553 (43.5%) 284 (47.7%) 1,269 (42.6%)
20–200 754 (21.1%) 116 (19.5%) 638 (21.4%) 0.07
.200 1,264 (35.4%) 195 (32.8%) 1,069 (35.9%)
How was HCC diagnosed?
Part of screening 927 (27.3%) 118 (21.6%) 809 (28.4%) 0.001
Incidental 442 (13.0%) 86 (15.8%) 356 (12.5%) 0.04
Symptoms workup 1,880 (55.3%) 327 (59.9%) 1,553 (54.5%) 0.02
Other 7 (0.2%) 2 (0.4%) 5 (0.2%) 0.37
NA/unknown 169 (5.0%) 19 (3.5%) 150 (5.3%) 0.08
Regular surveillance within 2 yr before HCC?
Yes 984 (28.9%) 121 (22.0%) 863 (30.2%) 0.0003
Unknown 1,291 (37.9%) 220 (40.0%) 1,071 (37.5%)
Method of diagnosis
Histology 2,845 (69.4%) 451 (67.3%) 2,394 (69.8%) 0.21
Imaging 3,842 (93.7%) 633 (94.5%) 3,209 (93.5%) 0.36
Other 24 (0.6%) 4 (0.6%) 20 (0.6%) 0.97
Unknown 4 (0.1%) 0 (0.0%) 4 (0.1%) 0.38
Anatomic stage
Stage I 1,173 (31.9%) 176 (29.9%) 997 (32.3%)
Stage II 706 (19.2%) 109 (18.5%) 597 (19.4%)
Stage IIIA 420 (11.4%) 72 (12.2%) 348 (11.3%)
Stage IIIB 567 (15.4%) 92 (15.6%) 475 (15.4%) 0.09
Stage IIIC 52 (1.4%) 2 (0.3%) 50 (1.6%)
Stage IVA 203 (5.5%) 38 (6.5%) 165 (5.4%)
Stage IVB 551 (15.0%) 99 (16.8%) 452 (14.7%)
Anatomic stage category
Stage I or II 1,879 (51.2%) 285 (48.5%) 1,594 (51.7%) 0.09
Stage III or IV 1,793 (48.8%) 303 (51.5%) 1,490 (48.3%)
Tumor differentiation
Well 759 (32.6%) 136 (38.0%) 623 (31.6%) 0.006
Moderate 1,066 (45.8%) 159 (44.4%) 907 (46.1%)
Poor 486 (20.9%) 58 (16.2%) 428 (21.7%)
Undifferentiated/anaplastic 16 (0.7%) 5 (1.4%) 11 (0.6%)
Tumor stage
Single 1,414 (34.9%) 206 (31.2%) 1,208 (35.6%)
3 tumors ,3 cm 328 (8.1%) 47 (7.1%) 281 (8.3%)
Large multinodular 867 (21.4%) 157 (23.8%) 710 (20.9%) 0.08
Vascular invasion or extrahepatic spread 1,447 (35.7%) 250 (37.9%) 1,197 (35.2%)
Tumor within the Milan criteria 1,377 (33.7%) 200 (30.0%) 1,177 (34.4%) 0.06
AFP, alpha fetoprotein; HCC, hepatocellular carcinoma; NA, not applicable.
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Table 4. Tumor characteristics comparing alcohol plus viral etiology and nonalcohol etiologies
Variable Overall, N 5 4,657 Alcohol plus viral etiology, N 5 1,226 Nonalcohol etiology, N 5 3,431 P value
Tumor size (cm) 4.4 (2.6, 8.0) 3.7 (2.4, 5.9) 4.7 (2.7, 8.9) ,0.001
AFP (ng/mL) 39.6 (7.3, 722.9) 37.5 (9.0, 411.5) 41.2 (6.7, 872.3) 0.59
AFP category
,20 1,721 (42.1%) 452 (40.7%) 1,269 (42.6%)
20–200 942 (23.0%) 304 (27.4%) 638 (21.4%) ,0.001
.200 1,424 (34.8%) 355 (32.0%) 1,069 (35.9%)
How was HCC diagnosed?
Part of screening 1,054 (27.9%) 245 (26.3%) 809 (28.4%) ,0.001
Incidental 440 (11.6%) 84 (9.0%) 356 (12.5%) ,0.001
Symptoms workup 2,111 (55.8%) 558 (59.9%) 1,553 (54.5%) ,0.001
Other 8 (0.2%) 3 (0.3%) 5 (0.2%) ,0.001
NA/unknown 199 (5.3%) 49 (5.3%) 150 (5.3%) ,0.001
Regular surveillance within 2 yr before HCC?
Yes 1,175 (31.0%) 312 (33.4%) 863 (30.2%) ,0.001
Unknown 1,448 (38.2%) 377 (40.4%) 1,071 (37.5%)
Method of diagnosis
Histology 3,068 (65.9%) 674 (55.0%) 2,394 (69.8%) ,0.001
Imaging 4,350 (93.4%) 1,141 (93.1%) 3,209 (93.5%) 0.58
Other 23 (0.5%) 3 (0.2%) 20 (0.6%) 0.15
Unknown 6 (0.1%) 2 (0.2%) 4 (0.1%) 0.70
Anatomic stage
Stage I 1,320 (32.0%) 323 (31.0%) 997 (32.3%)
Stage II 883 (21.4%) 286 (27.5%) 597 (19.4%)
Stage IIIA 457 (11.1%) 109 (10.5%) 348 (11.3%)
Stage IIIB 602 (14.6%) 127 (12.2%) 475 (15.4%) ,0.001
Stage IIIC 60 (1.5%) 10 (1.0%) 50 (1.6%)
Stage IVA 216 (5.2%) 51 (4.9%) 165 (5.4%)
Stage IVB 587 (14.2%) 135 (13.0%) 452 (14.7%)
Anatomic stage category
Stage I or II 2,203 (53.4%) 609 (58.5%) 1,594 (51.7%) ,0.001
Stage III or IV 1,922 (46.6%) 432 (41.5%) 1,490 (48.3%)
Tumor differentiation
Well 796 (31.7%) 173 (32.1%) 623 (31.6%) ,0.001
Moderate 1,168 (46.6%) 261 (48.4%) 907 (46.1%)
Poor 529 (21.1%) 101 (18.7%) 428 (21.7%)
Undifferentiated/anaplastic 15 (0.6%) 4 (0.7%) 11 (0.6%)
Tumor stage
Single 1,610 (34.9%) 402 (33.1%) 1,208 (35.6%) ,0.001
3 tumors , 3 cm 444 (9.6%) 163 (13.4%) 281 (8.3%)
Large multinodular 995 (21.6%) 285 (23.5%) 710 (20.9%)
Vascular invasion or extrahepatic spread 1,560 (33.8%) 363 (29.9%) 1,197 (35.2%)
Tumor within the Milan criteria 1,689 (36.4%) 512 (42.0%) 1,177 (34.4%) ,0.001
AFP, alpha fetoprotein; HCC, hepatocellular carcinoma; NA, not applicable.
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MELD score (11 vs 10, P 5 0.004), and more evidence of clinical
decompensation as assessed by Pugh-Child’s class B/C status (51.6%
vs39.6%,P,0.001) comparedwith theNAFLDHCCsubgroup.The
degree of underlying hepatic dysfunction as appraised biochemically
and clinically did not appreciably change in the NAFLD subgroup
analysis relative to the overall cohort. The tumor characteristics of the
NAFLD subgroup largely mirrored the overall nonalcohol cohort as
well. Although there was no significant difference in greatest tumor
size between alcohol-alone vs NAFLD-alone HCCs (4.7 vs 5.0 cm, P
50.13),NAFLDassociatedHCCsweremore likely thanALD-alone-
related HCCs to present as single tumors (31.2% vs 40.5%) and less
likely to present with vascular invasion or extrahepatic spread 37.9%
vs 32.1%) (P5 0.004 for overall tumor stage).
Trend of ALD-related HCC over the study period
We contrasted the features of ALD-alone-related HCC during 3
diagnostic periods of time (2000–2004, 2005–2009, and
2010–2014) (Table 5). The age at HCC diagnosis did not signifi-
cantly change during the 3 time periods in the alcohol-alone group
(P 5 0.10), but the maximum tumor size decreased significantly
between 2000 and 2004 (6 cm) and the latter 2 eras (4.3 and 4.4 cm,
respectively, P 5 0.0004). Median AFP values at HCC diagnosis
also decreased significantly over the 3 time periods (77.2 vs 42.2 vs
14.9, P 5 0.007). Predictably, the diagnosis of HCC by screening
was highest during themost recent era (27.6%) compared with the
earlier 2 eras (14.5% and 14%, P , 0.001), which accordingly
translated to earlier anatomic stage tumors that were more fre-
quently within the Milan criteria (16% vs 31% vs 35%, P, 0.001).
Features of noncirrhotic HCC in ALD
Interestingly, noncirrhoticHCCwas seldom seen in theALD-alone
group compared with the cohort without documented ALD (6.6%
vs 15.7%,P, 0.001).NoncirrhoticHCCwas also exceptionally rare
in the ALD plus viral cohort occurring in only 22 of 1,226 cases
(1.8%). The striking male predominance of ALD-related HCC was
accentuated in noncirrhotic patients with only 7.6% occurring in
women in the combined ALD-alone and ALD plus viral cohorts
compared with 37.1% in the nonalcohol group (P , 0.001). At
diagnosis, the ALD and viral cohorts’ largest tumor size was 5.1 cm,
which was significantly smaller than the alcohol-alone (8.2 cm) and
nonalcohol (8.5 cm) cohorts (P5 0.03).However, the differences in
tumor sizes did not translate to statistically significant differences in
anatomic stage or tumor differentiation.
Treatment and survival of patients with ALD-related HCC
Patients with alcohol-alone-related HCC were less likely to
undergo surgical resection (8.1% vs 15.4%, P, 0.001) and liver
transplantation (11.5% vs 16.8%, P5 0.0005) but more likely to
receive palliative care (29.3% vs 23.4%, P5 0.001) than patients
in the nonalcohol cohort (see Table 3, Supplementary Digital
Content 1, http://links.lww.com/CTG/A223). By contrast, the
alcohol and viral cohort had the lowest rate of resection (6.6%,
P , 0.001) but the highest rate of liver transplantation (19.5%,
P 5 0.04) and exposure to palliative care services
(31.5%, P, 0.001).Median survival was significantly reduced in
patients in the ALD-alone HCC cohort (1.07 years [95% CI:
0.88–1.29]) compared with the ALD plus viral group (1.31 years
[95% CI: 1.17–1.46], P5 0.002) and the non-ALD cohort group
(1.41 years [95% CI: 1.32–1.51], P , 0.001) (Figure 2).
DISCUSSION
Our consortium of over 5,000 HCC cases from centers encom-
passing awide geographic area of theUnited States illustrates salient
features of ALD-related HCC relative to HCCs occurring in other
CLDs.We have reaffirmed in our US-based cohort findings seen in
European andNorthAmerican cohorts thatALD-relatedHCCs are
overly represented in male patients (10,14,24). Male gender was
associated with almost 4 times the odds of having HCC irrespective
Table 5. Selected features of alcohol-alone-related HCC by era of diagnosis
Variable Overall, N5 670
Diagnosis date
P value2000–2004, N 5 145 2005–2009, N 5 156 2010–2014, N5 369
Age at HCC diagnosis 65.0 (59.0, 71.0) 66.0 (61.0, 71.0) 65.5 (59.0, 70.0) 64.0 (58.0, 71.0) 0.10
Male sex 610 (91.0%) 131 (90.3%) 142 (91.0%) 337 (91.3%) 0.94
Obesity 238 (40.5%) 39 (36.8%) 47 (33.3%) 152 (44.6%) ,0.001
APRI $ 1.0 365 (59.3%) 62 (54.9%) 87 (58.4%) 216 (61.0%) ,0.001
MELD score 11.0 (8.0, 14.0) 10.0 (8.0, 13.0) 10.0 (8.0, 14.0) 11.0 (9.0, 15.0) 0.10
Tumor size 4.7 (3.0, 8.1) 6.0 (3.8, 10.0) 4.3 (2.9, 8.1) 4.4 (2.7, 7.1) 0.0004
AFP (ng/mL) 25.8 (5.5, 876.1) 77.2 (7.4, 1,897) 42.2 (5.7, 876.1) 14.9 (4.8, 530.0) 0.007
HCC diagnosed by screening 118 (21.6%) 19 (14.5%) 16 (14.0%) 83 (27.6%) ,0.001
Tumor stage
Single 206 (31.2%) 27 (19.1%) 48 (32.0%) 131 (35.5%) ,0.001
3 tumors , 3 cm 47 (7.1%) 6 (4.3%) 12 (8.0%) 29 (7.9%)
Large multinodular 157 (23.8%) 41 (29.1%) 40 (26.7%) 76 (20.6%)
Vascular invasion or extrahepatic spread 250 (37.9%) 67 (47.5%) 50 (33.3%) 133 (36.0%)
Tumor within Milan the criteria 200 (30.0%) 23 (16.0%) 48 (31.4%) 129 (35.0%) ,0.001
APRI, AST to Platelet Ratio Index; AFP, alpha fetoprotein; HCC, hepatocellular carcinoma; MELD, model for end-stage liver disease.
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of underlying CLD from the US Surveillance, Epidemiology, and
End Results-Medicare database (25). Data from the US Census
foundHCC-relatedmortality rates inmen tobe3.4-foldhigher than
in woman (5). Patients with alcohol-related HCC from our cohort
were diagnosed at an older age than corresponding cases in the
alcohol and viral cohort and the nonalcohol cohorts. Our finding
contrasts with the Italian Liver Cancer Database in which ALD-
related HCCs over a similar time period presented at a younger age
than HCV-related HCCs (66.7 vs 70.7, P , 0.001) (10). A recent
retrospective study from an ethnically diverse population in Dallas
found NASH-related HCC to occur at an older age than both ALD
and HCV-associated HCC (67.9 vs 59.7 vs 58.2, respectively, P ,
0.001) (26). Nonetheless, older age has consistently been identified
as independently associated with HCC risk in patients with CLD,
regardless of etiology (15,24).
The alcohol plus viral hepatitis cohort almost exclusively
contained patients with HCV, and while our study period pre-
dated the availability of direct-acting antiviral therapy, the anal-
yses validate the synergism between alcohol and HCV-associated
HCC (27). These patients developed HCCs at a significantly
earlier age and overall were more likely to have cirrhosis com-
plications than the alcohol-alone and nonalcohol cohorts. This
finding, however, should be viewed within the context of a higher
frequency of surveillance as the HCC diagnostic methodology in
the alcohol and viral cohort relative to the alcohol-alone group.
In contrast to Surveillance, Epidemiology, and End Results andUS
VeteransAffairs data that rely on International StatisticalClassification
of Diseases-9 and International Statistical Classification of Diseases-10
classification, our cohort characterizedpatientsdirectly fromindividual
medical records (25,28). To our knowledge, the HCC cases from our
consortium represent the largest US cohort with direct ascertainment
of tumor variables and treatmentmodalities.ALD-alone-relatedHCCs
were most likely to present as large and multinodular tumors with
evidence of vascular invasion or extrahepatic spread and correspond-
inglywere rarely treatedby liver transplantation.Moreover, unadjusted
survival in thealcohol-alonecohortwas significantly shorter than in the
other 2 groups. Across the 3 distinct time periods, 2000–2004,
2004–2009, and 2010–2014, the frequency of HCC surveillance in the
alcohol-alone cohort increased, resulting inmore tumors diagnosed at
an early stage and improved survival.
A strength of our cohort is the sizable proportion of noncirrhotic
HCC cases. Remarkably, there were very few cases of noncirrhotic
ALD-related HCC (6.6%), far fewer than in the nonalcohol cohort
(15.7%), and comparatively less than theUSVeteransAffairs cohort
of 11.1% noncirrhotic alcohol-related HCCs identified using the
same criteria for the absence of cirrhosis (23). Notably, the fre-
quency of noncirrhoticALD-relatedHCCdid not change over the 3
different timeperiods. Since the largest burdenofnoncirrhoticHCC
is arising on a background of NAFLD, it is curious that features of
metabolic syndrome, common to both alcohol and NAFLD, have
not translated to a similar increase in noncirrhotic ALD-related
HCC. Given shared genetic and inflammatory underpinnings of
toxic-metabolic liver injury, one speculates whether the differences
are a result of epigenetic variation.
In summary, our detailed examination of patients with ALD-
related HCCs highlights several features. The striking pre-
dominance of older male patients with ALD-alone-related HCCs
is noteworthy. Moreover, the diagnosis of HCC in this group
Figure 2. (a) Survival analysis for 3 cohorts. (b) Log-rank test.
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often occurred belatedly with a correspondingly negative impact
on survival relative to patients with HCC in the absence of ALD.
The ALD plus viral HCC cohort contrasts nicely with the ALD-
alone cohort. As anticipated, the combined cohort had more
advanced cirrhotic features and their HCCs were diagnosed at
a younger age. They survived longer than patients in the ALD-
alone group and had the highest likelihood of receiving a liver
transplant among the 3 groups. Last, noncirrhotic HCC was
a truly rare occurrence in patients with ALD.
The results of our study emphasize the need to identify patients
at risk for alcohol use disorder, ALD, and alcohol-related cirrhosis
for linkage to care. As a preventable disease, it is disturbing that
mortality rates from ALD are increasing. Our large data set rein-
forces the consequences of a delayed diagnosis of HCC in patients
with ALD and should prompt renewed attention to addressing the
increasing prevalence of alcohol consumption and ALD globally.
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Study Highlights
WHAT IS KNOWN
3 The magnitude of ALD globally is alarming.
3 Mortality in ALD is often because of HCC.
WHAT IS NEW HERE
3 HCC in ALD occurs predominantly in older men.
3 Patients with ALD-related HCCs present with advanced
tumors outside the Milan criteria.
3 Survival after HCC diagnosis is lower in ALD relative to other
CLDs.
TRANSLATIONAL IMPACT
3 Identifying patients at risk for ALD is critical to prevent the
adverse consequences of cirrhosis and HCC.
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